Marie Fallon - Ginkgo Bioworks Chief Officer
| DNA Stock | USD 8.70 0.44 5.33% |
Insider
Marie Fallon is Chief Officer of Ginkgo Bioworks Holdings
| Address | 27 Drydock Avenue, Boston, MA, United States, 02210 |
| Phone | 877 422 5362 |
| Web | https://www.ginkgobioworks.com |
Ginkgo Bioworks Management Efficiency
The company has Return on Asset of (0.2092) % which means that on every $100 spent on assets, it lost $0.2092. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.6351) %, meaning that it generated no profit with money invested by stockholders. Ginkgo Bioworks' management efficiency ratios could be used to measure how well Ginkgo Bioworks manages its routine affairs as well as how well it operates its assets and liabilities. As of November 30, 2024, Return On Tangible Assets is expected to decline to -0.61. In addition to that, Return On Capital Employed is expected to decline to -0.6. At present, Ginkgo Bioworks' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 107.1 M, whereas Net Tangible Assets are forecasted to decline to about 1.1 B.Similar Executives
| Showing other executives | INSIDER Age | ||
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Kirk Coleman | Tff Pharmaceuticals | 50 | |
| James JD | Eliem Therapeutics | 58 | |
| BS CPA | Inhibrx | 42 | |
| Harlan Weisman | Tff Pharmaceuticals | 72 | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
| Dale Christensen | Tff Pharmaceuticals | N/A | |
| Mark Lappe | Inhibrx | 57 | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Glenn Mattes | Tff Pharmaceuticals | 67 | |
| Anthony Hickey | Tff Pharmaceuticals | N/A | |
| Quinn Deveraux | Inhibrx | N/A | |
| Paul Manley | Tff Pharmaceuticals | N/A | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| MBA MD | Eliem Therapeutics | 63 | |
| Michael Pitzner | Molecular Partners AG | N/A | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Christopher Cano | Tff Pharmaceuticals | 53 | |
| Robert MBA | Eliem Therapeutics | 56 | |
Management Performance
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.21 |
Ginkgo Bioworks Holdings Leadership Team
Elected by the shareholders, the Ginkgo Bioworks' board of directors comprises two types of representatives: Ginkgo Bioworks inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ginkgo. The board's role is to monitor Ginkgo Bioworks' management team and ensure that shareholders' interests are well served. Ginkgo Bioworks' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ginkgo Bioworks' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anna Wagner, Senior Development | ||
| Samantha Sutton, Head People | ||
| Joaquim Marques, Head Chemistry | ||
| Mark Dmytruk, Chief Officer | ||
| Reshma Shetty, President, Founder | ||
| Joshua Dunn, Head Design | ||
| Thomas Knight, Founder | ||
| Austin Che, Head Founder | ||
| Karen Tepichin, General Secretary | ||
| Steven CPA, Chief Officer | ||
| Jason Kelly, CEO Founder | ||
| Marie Fallon, Chief Officer | ||
| Bartholomew Canton, CTO Founder | ||
| Anna MBA, Senior Development |
Ginkgo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ginkgo Bioworks a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (2.99) % | ||||
| Operating Margin | (0.59) % | ||||
| Current Valuation | 304.15 M | ||||
| Shares Outstanding | 45.2 M | ||||
| Shares Owned By Insiders | 6.15 % | ||||
| Shares Owned By Institutions | 68.50 % | ||||
| Number Of Shares Shorted | 7.32 M | ||||
| Price To Earning | 25.51 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ginkgo Bioworks Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ginkgo Bioworks' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ginkgo Bioworks Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ginkgo Bioworks Holdings Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ginkgo Bioworks Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ginkgo Bioworks. If investors know Ginkgo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ginkgo Bioworks listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (12.89) | Revenue Per Share 4.291 | Quarterly Revenue Growth 0.606 | Return On Assets (0.21) | Return On Equity (0.64) |
The market value of Ginkgo Bioworks Holdings is measured differently than its book value, which is the value of Ginkgo that is recorded on the company's balance sheet. Investors also form their own opinion of Ginkgo Bioworks' value that differs from its market value or its book value, called intrinsic value, which is Ginkgo Bioworks' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ginkgo Bioworks' market value can be influenced by many factors that don't directly affect Ginkgo Bioworks' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ginkgo Bioworks' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ginkgo Bioworks is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ginkgo Bioworks' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.